Comparing the effectiveness of Hepa-Mertz mono therapy versus rifaximin in patients presenting with hepatic encephalopathy

被引：0
|
作者：
Doyle, J. B. M. [1 ]
McDougall, N. I. [1 ]
Cash, W. J. [1 ]
机构：
[1] Royal Victoria Hosp, Liver Unit, Belfast BT12 6BA, Antrim, North Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2015年 / 184卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
32(14S161)
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 48 条
  • [11] Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed
    Maharshi, Sudhir
    Sharma, Barjesh Chander
    Srivastava, Siddharth
    Jindal, Amit
    GUT, 2015, 64 (08) : 1341 - +
  • [12] Efficacy and Safety of Rifaximin Monotherapy Versus Lactulose Combination Therapy for the Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
    Sanyal, Arun J.
    Hassanein, Tarek I.
    Kayali, Zeid
    Kang, Robert
    Wolf, Ray A.
    Mullen, Kevin D.
    HEPATOLOGY, 2016, 64 : 130A - 131A
  • [13] Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy
    Patel, Ankoor H.
    Li, You
    Minacapelli, Carlos D.
    Catalano, Kaitlyn
    Rustgi, Vinod
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (02)
  • [14] EVALUATION OF PATIENTS HOSPITALIZED WITH HEPATIC ENCEPHALOPATHY AND PRESCRIBED RIFAXIMIN THERAPY AT A SINGLE MULTI-DISCUPLINARY CENTER
    Kulkarni, Archana A.
    Arif, Hamza
    Pronesti, Vincent M.
    Frank, Evanee
    Babich, Michael
    Kapetanos, Anastasios
    GASTROENTEROLOGY, 2018, 154 (06) : S730 - S730
  • [15] RISK REDUCTION IN GASTROINTESTINAL CANCERS IN CIRRHOTIC PATIENTS RECEIVING LACTULOSE, RIFAXIMIN, OR COMBINATION THERAPY FOR HEPATIC ENCEPHALOPATHY
    Patel, Ankoor H.
    Li, You
    Minacapelli, Carlos D.
    Catalano, Carolyn
    Rustgi, Vinod K.
    GASTROENTEROLOGY, 2023, 164 (06) : S1328 - S1328
  • [16] Genomic Characterization of Stool Microbiota With Rifaximin Monotherapy Versus Lactulose Combination Therapy for Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
    Dupont, Herbert L.
    Hassanein, Tarek I.
    Sanyal, Arun J.
    Wolf, Ray A.
    Mullen, Kevin D.
    HEPATOLOGY, 2016, 64 : 720A - 721A
  • [17] CONSERVATIVE ORAL THERAPY VERSUS RIFAXIMIN PLUS LACTOSE: WHICH IS A BETTER OPTION TO MANAGE RECURRENCE ONSET OF HE (HEPATIC ENCEPHALOPATHY)
    Andaleeb, Hina
    Zafar, Ayesha
    Jamil, Rabia
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (03): : 5338 - 5344
  • [18] Reversal of Low-Grade Cerebral Edema After Lactulose/Rifaximin Therapy in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
    Rai, Rahul
    Ahuja, Chirag K.
    Agrawal, Swastik
    Kaira, Naveen
    Duseja, Ajay
    Khandelwal, Niranjan
    Chawla, Yogesh
    Dhiman, Radha K.
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2015, 6
  • [19] MELD BASED COMPARISON OF HOSPITALIZATIONS FROM HEPATIC ENCEPHALOPATHY IN PATIENTS WITH ADVANCED LIVER DISEASE ON RIFAXIMIN AND LACTULOSE COMBINATION THERAPY
    Hassett, Molly
    Ramireddy, Silpa
    Mantry, Parvez S.
    HEPATOLOGY, 2011, 54 : 1263A - 1264A
  • [20] Cost-Effectiveness of Rifaximin/alpha versus Lactulose in preventing recurrent episodes of overt hepatic encephalopathy: a systematic review and meta-analysis
    Siddiqui, Kashif
    Attri, Sumeet
    Olando, Massimo
    Lelli, Filippo
    Maida, Valeria
    Thabut, Dominique
    JOURNAL OF HEPATOLOGY, 2021, 75 : S356 - S357
12345